Navigation Links
AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB
Date:11/13/2007

TUSTIN, Calif., Nov. 13 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL) reported today that it has filed a Form 12b-25 with the Securities and Exchange Commission indicating that its Form 10-QSB for the six months ended September 30, 2007 would not be filed by November 14, 2007. However, AMDL expects to file the required report by November 19, 2007, in the time allotted by the Rules. Gary L. Dreher, President, stated: "Accounting for our operations in China is challenging and we need the additional time to properly prepare the Form 10-QSB."

About AMDL

AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voic
'/>"/>

SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
(Date:8/20/2014)... N.C. , Aug. 20, 2014 ... research services located in Raleigh, NC ... Bradford Evans as Vice President of Administration. ... Brad will oversee all corporate processes, including their ... joining Clintrax Global, Brad worked as an HR ...
(Date:8/20/2014)... in measuring vibrational motion of a single molecule with ... of a single molecule differs from the behaviour of ... at the University of California, Irvine, where post-doctoral researcher ... a visiting fellow under professor Vartkess A. Apkarian, whose ... lead by Professor Eric O. Potma. The results of ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014  Decision Resources Group ... , Russia , India ... approximately $1.6 billion in 2013, roughly equal to the size of ... forward, however, the BRIC market will experience much faster growth as ... the aging population. Other key findings from Decision Resources ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... and LEXINGTON, Massachusetts, August 25, 2011 Shire ... specialty biopharmaceutical company, today announced that the U.S. Food and ... (icatibant injection) for treatment of acute attacks of hereditary ... "Until now, HAE patients faced challenges gaining rapid ...
... CBI, a division of Advanstar Communications, is pleased ... Tufts Center for the Study of Drug Development and ... the keynote speaker at their Pharma/Bio Forum on Preclinical ... at the Hyatt Harborside in Boston, MA. Dr. Kaitin ...
... school science teachers will explore the nanotechnology field at ... build interest in science and engineering. ... of Engineering a $429,000 grant to fund "Innovations in ... Starting next summer, selected middle and high school ...
Cached Biology Technology:FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 6Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference 2University of Houston receives NSF grant for high school teachers program 2
(Date:8/21/2014)... involves the pancreas digesting itself resulting in severe abdominal ... UK around 20,000 patients are diagnosed with the disease ... and treatment is restricted to intravenous fluid and nutritional ... of Life Sciences, who led the research, said "The ... gall stones and excessive alcohol intake combined with a ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... second most common cause of childhood blindness in the ... earlier than or at 28 weeks gestational age. The ... the retina of the eye. ROP risk increases with ... Brigham and Women,s Hospital (BWH) suggests that the antioxidant, ...
... young researchers were named Pew Scholars in the Biomedical ... join a prestigious community that includes Nobel Prize winners, ... Research Award. "During these challenging budgetary ... harder for scientists to obtain, we are proud to ...
... heavy rain, the lid of Nepenthes gracilis ... shelter on its underside directly into the fluid-filled pitcher, ... Wednesday 13 June, in the journal PLoS ONE ... a source of nutrients, enabling them to colonise nutrient-poor ...
Cached Biology News:Antioxidant shown to reduce blindness risk in extremely premature babies 222 of America's most promising scientists selected as Pew Biomedical Scholars 222 of America's most promising scientists selected as Pew Biomedical Scholars 3Pitcher plant uses rain drops to capture prey 2
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
Biology Products: